Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Section H Update

for Hospital Pharmaceuticals

December 2023

PHARMAC
TE PĀTAKA WHAIORANGA

Contents

Summary of decisions
EFFECTIVE 1 DECEMBER 2023

- Amoxicillin (Miro-Amoxicillin) cap 250 mg and 500 mg – new listing and addition of PSS
- Amoxicillin (Alphamox) cap 250 mg and 500 mg – to be delisted 1 May 2024
- Aspirin (Ethics Aspirin) tab dispersible 300 mg – price increase and addition of PSS
- Atazanavir sulphate (Atazanavir Viatris) cap 200 mg – new listing
- Atenolol (Mylan Atenolol) tab 100 mg – to be delisted 1 July 2024
- Barium sulphate grans for oral liq 960 mg per g (96% w/w), 176 g bottle (Vanilla SilQ MD) and grans for oral liq 980 mg per g (98% w/w), 310 g bottle (Vanilla SilQ HD) – amended presentation description
- Betaxolol eye drops 0.25% (Betoptic S) and eye drops 0.5% (Betoptic) – to be delisted 1 July 2025
- Brentuximab vedotin (Adcetris) inj 50 mg vial – new listing
- Bupropion hydrochloride (Zyban) tab modified-release 150 mg – price increase and addition of PSS
- Cefuroxime (Cefuroxime Devatis) inj 750 mg vial and 1.5 g vial – new listing and addition of PSS
- Cefuroxime (Cefuroxime-AFT) inj 750 mg vial and 1.5 g vial – to be delisted 1 May 2024
- Chlorhexidine soln 0.1% – new listing
- Compound electrolytes with glucose [Dextrose] (Hydralyte – Lemonade) soln with electrolytes, 1,000 ml – new listing and addition of PSS
- Compound electrolytes with glucose [Dextrose] (Pedialyte - Bubblegum) soln with electrolytes (2 x 500 ml) – to be delisted 1 May 2024
- Dexmedetomidine (Dexmedetomidine Viatris) inj 100 mcg per ml, 2 ml vial – new listing and addition of PSS
- Dexmedetomidine (Dexmedetomidine-Teva) inj 100 mcg per ml, 2 ml vial – to be delisted 1 May 2024
- Diatrizoate meglumine with sodium amidotrizoate (Gastrografin S29 and Gastrografin Ger) oral liquid 660 mg per ml with sodium amidotrizoate 100 mg per ml, 100 ml bottle – new listing
- Emulsifying ointment (Emulsifying Ointment ADE) oint BP, 500 g – price decrease and addition of PSS
- Glycomacropeptide and amino acid contains some phenylalanine (PKU GMPro Ultra Lemonade, PKU Build 20 Chocolate, PKU Build 20 Raspberry Lemonade, PKU Build 20 Smooth, PKU Build 20 Vanilla, PKU sphere20 Lemon, PKU sphere20 Chocolate, PKU sphere20 Red Berry, PKU sphere20 Vanilla, PKU sphere20 Banana) delayed delisting date to 1 March 2024

Summary of decisions – effective 1 December 2023 (continued)

- High protein oral feed 2.4 kcal/m (e.g. Fortisip Compact Protein) liquid 14.6 g protein, 25.3 g carbohydrate and 9.6 g fat per 100 ml,125 ml bottle – delayed delisting date to 1 December 2024
- Ibuprofen (Relieve) tab 200 mg – 1,000 tablet pack – extend HSS end date
- Ibuprofen (Relive) tab 200 mg – 20 tablet pack – to be delisted 1 June 2024
- Imatinib mesylate (Imatinib-Rex) cap 100 mg and 400 mg – removal of note
- Iohexol (Omnipaque) inj 350 mg per ml (iodine equivalent), 75 ml bottle – new Pharmacode listing
- Iohexol (Omnipaque) inj 350 mg per ml (iodine equivalent), 75 ml bottle – delisted 1 December 2023
- Ketoconazole (Sebizole) shampoo 2%, 100 ml – price increase and addition of PSS
- Low-GI enteral feed 1 kcal/ml (e.g. Nutrison Advanced Diason) Liquid 4.3 g protein, 11.3 g carbohydrate and 4.2 g fat per 100 ml, 1,000 ml bottle – to be delisted 1 July 2024
- Meningococcal B multicomponent vaccine (Bexsero) inj 175 mcg per 0.5 ml prefilled syringe – new Pharmacode listing
- Methyldopa (Methyldopa Viatris) tab 250 mg – new listing
- Miconazole nitrate (Multichem) crm 2%, 15 g – price increase and addition of PSS
- Morphine sulphate (Wockhardt) oral liq 2 mg per ml, 100 ml – new listing
- Naproxen (Noflam 500) tab 500 mg – new Pharmacode listing
- Nevirapine (Nevirapine Alphapharm) tab 200 mg – to be delisted 1 July 2024
- Nicorandil (Max Health) tab 10 mg and 20 mg – new listing and addition of PSS
- Nicorandil (Ikorel) tab 10 mg and 20 mg – to be delisted 1 May 2024
- Nimodipine (Nimotop) inj 0.2 mg per ml, 50 ml vial, 5 inj – amended presentation description and addition of PSS
- Nimodipine (Nimotop) inj 0.2 mg per ml, 50 ml vial, 1 inj – amended delist date to 1 May 2024
- Olanzapine (Zyprexa Relprevv) inj 210 mg vial, 200 mg vial and 405 mg vial – addition of note
- Paracetamol tab 500 mg – blister pack – 1,000 tablet pack (Pacimol) and bottle pack (Noumed Paracetamol) – extend HSS end date
- Pravastatin (Clinect) tab 20 mg and 40 mg – new listing and addition of PSS
- Pravastatin (Pravastatin Mylan) tab 20 mg – to be delisted from 1 May 2024
- Pravastatin tab 20 mg (Pravastatin Viatris) and tab 40 mg (Pravastatin Mylan) – to be delisted 1 May 2024

Summary of decisions – effective 1 December 2023 (continued)

- Propamidine isethionate eye drops 0.1% – new listing
- Tramadol hydrochloride tab sustained-release 100 mg (Tramal SR 100), tab sustained-release 150 mg (Tramal SR 150), tab sustained-release 200 mg (Tramal SR 1200), inj 50 mg per ml, 1 ml ampoule (Tramal 50) and inj 50 mg per ml, 2 ml ampoule (Tramal 100) – price increase and addition of PSS
- Trastuzumab (Herceptin) (Herceptin) inj 150 mg vial and 440 mg vial – amended chemical name, restriction criteria and to be delisted 1 June 2024
- Trastuzumab (Herzuma) (Herzuma) inj 150 mg vial and 440 mg vial – new listing and addition of PSS
- Zidovudine [AZT] with lamivudine (Alphapharm) tab 300 mg with lamivudine 150 mg – to be delisted 1 July 2024

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Section H changes to Part II

Effective 1 December 2023

BLOOD AND BLOOD FORMING ORGANS

41 COMPOUND ELECTROLYTES WITH GLUCOSE [DEXTROSE] (new listing and addition of PSS)
Soln with electrolytes – **5% DV May-24 to 2025** ..... 6.53 1,000 ml **Hydralyte – Lemonade**
Note – Pedialyte – Bubblegum soln with electrolytes (2 x 500 ml) to be delisted from 1 May 2024

CARDIOVASCULAR SYSTEM

46 ATENOLOL (delisting)
Tab 100 mg – **5% DV Jan-22 to 2024** ..... 14.20 500 **Mylan Atenolol**
Note – Mylan Atenolol tab 100 mg to be delisted from 1 July 2024

48 NIMODIPINE (amended presentation description, delist date and addition of PSS)
Inj ~~200 mcg~~ **0.2 mg** per ml, 50 ml vial
– **5% DV May-24 to 2025** ..... 337.50 5 **Nimotop**
Note – Nimotop inj 0.2 mg per ml, 50 ml vial, 1 vial to be delisted from 1 ~~April~~ **May** 2024

49 METHYLDOPA (new listing)
Tab 250 mg ..... 15.10 100 Methyldopa Viatris

51 PRAVASTATIN (delayed delisting date)
Tab 20 mg ..... 2.11 28 Pravastatin Mylan
Note – Pravastatin Mylan tab 20 mg to be delisted 1 ~~January~~ **May** 2024

51 PRAVASTATIN (new listing and addition of PSS)
Tab 20 mg – **5% DV May-24 to 2026** ..... 7.16 100 **Clinect**
Tab 40 mg – **5% DV May-24 to 2026** ..... 12.25 100 **Clinect**
Note – Pravastatin Viatris tab 20 mg and Pravastatin Mylan tab 40 mg to be delisted 1 May 2024

55 NICORANDIL (new listing and addition of PSS)
Tab 10 mg – **5% DV May-24 to 2025** ..... 21.73 60 **Max Health**
Tab 20 mg – **5% DV May-24 to 2025** ..... 27.44 60 **Max Health**
Note – Ikorel tab 10 mg and 20 mg to be delisted from 1 May 2024

DERMATOLOGICALS

67 KETOCONAZOLE (↑ price and addition of PSS)
Shampoo 2% – **5% DV May-24 to 2026** ..... 4.09 100 ml **Sebizole**

67 MICONAZOLE NITRATE (↑ price and addition of PSS)
Crm 2% – **5% DV May-24 to 2026** ..... 0.90 15 g **Multichem**

69 EMULSIFYING OINTMENT (↓ price and addition of PSS)
Oint BP, 500 g – **5% DV May-24 to 2026** ..... 3.13 500 g **Emulsifying Ointment ADE**

Note: DV limit applies to pack sizes of greater than 200 g.

➔ Restriction
(Brand) indicates a brand example only. It is not a contracted product.

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 December 2023 (continued)

INFECTIONS

89 CEFUROXIME (new listing and addition of PSS)

Inj 750 mg vial – **5% DV May-24 to 2026**	8.16	10	**Cefuroxime Devatis**
Inj 1.5 g vial – **5% DV May-24 to 2026**	13.01	10	**Cefuroxime Devatis**

Note – Cefuroxime-AFT inj 750 mg vial and 1.5 g vial to be delisted from 1 May 2024

92 AMOXICILLIN (new listing and addition of PSS)

Cap 250 mg – **5% DV May-24 to 2025**	27.50	500	**Miro-Amoxicillin**
Cap 500 mg – **5% DV May-24 to 2025**	41.00	500	**Miro-Amoxicillin**

Note – Alphamox cap 250 mg and 500 mg to be delisted from 1 May 2024

102 NEVIRAPINE (delisting)

➔ Tab 200 mg – **5% DV Jan-22 to 2024**	84.00	60	**Nevirapine Alphapharm**

Note – Nevirapine Alphapharm tab 200 mg to be delisted from 1 July 2024

103 ZIDOVUDINE [AZT] WITH LAMIVUDINE (delisting)

➔ Tab 300 mg with lamivudine 150 mg	92.40	60	Alphapharm

Note – Alphapharm tab 300 mg with lamivudine 150 mg to be delisted from 1 July 2024

103 ATAZANAVIR SULPHATE (new listing)

➔ Cap 200 mg	110.00	60	Atazanavir Viatris

MUSCULOSKELETAL SYSTEM

116 IBUPROFEN (extended HSS end date)

Tab 200 mg – 1,000 tablet pack			
– **1% DV Feb-21 to ~~2024~~ 2026**	21.40	1,000	**Relieve**

116 IBUPROFEN (delisting)

Tab 200 mg – 20 tablet pack	1.35	20	Relieve

Note – Relieve tab 200 mg – 20 tablet pack to be delisted from 1 June 2024

117 NAPROXEN (new listing)

Tab 500 mg – **5% DV Jan-22 to 2024**	28.71	250	**Noflam 500**

Note – new Pharmacode listings, 2654466

NERVOUS SYSTEM

119 DEXMEDETOMIDINE (new listing and addition of PSS)

Inj 100 mcg per ml, 2 ml vial – **5% DV May-24 to 2026**	42.00	5	**Dexmedetomidine Viatris**

Note – Dexmedetomidine-Teva inj 100 mcg per ml, 2 ml vial to be delisted from 1 May 2024

122 ASPIRIN (↑ price and addition of PSS)

Tab dispersible 300 mg – **5% DV May-24 to 2026**	5.65	100	**Ethics Aspirin**

123 PARACETAMOL (extended HSS end date)

Tab 500 mg – blister pack – 1,000 tablet pack			
– **1% DV Feb-22 to ~~2024~~ 2026**	19.75	1,000	**Pacimol**
Tab 500 mg – bottle pack – **1% DV Feb-22 to ~~2024~~ 2026**	17.92	1,000	**Noumed Paracetamol**

Changes to Section H Part II – effective 1 December 2023 (continued)

124 MORPHINE SULPHATE (new listing)

Oral liq 2 mg per ml	14.25	100 ml	Wockhardt

125 TRAMADOL HYDROCHLORIDE (↑ price and addition of PSS)

Tab sustained-release 100 mg – **5% DV May-24 to 2026**	1.95	20	**Tramal SR 100**
Tab sustained-release 150 mg – **5% DV May-24 to 2026**	2.95	20	**Tramal SR 150**
Tab sustained-release 200 mg – **5% DV May-24 to 2026**	3.80	20	**Tramal SR 200**
Inj 50 mg per ml, 1 ml ampoule – **5% DV May-24 to 2026**	10.00	5	**Tramal 50**
Inj 50 mg per ml, 2 ml ampoule – **5% DV May-24 to 2026**	9.00	5	**Tramal 100**

Note – this price increase and PSS applies to Pharmacodes 2149508, 2149532, 2149532, 471208 and 471216 respectively.

134 OLANZAPINE – Restricted: **For continuation only** (addition of note)

➔ Inj 210 mg vial	252.00	1	Zyprexa Relprevv
➔ Inj 300 mg vial	414.00	1	Zyprexa Relprevv
➔ Inj 405 mg vial	504.00	1	Zyprexa Relprevv

144 BUPROPION HYDROCHLORIDE (↑ price and addition of PSS)

Tab modified-release 150 mg – **5% DV May-24 to 2026**	15.00	30	**Zyban**

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

158 IMATINIB MESILATE (removal of note)

~~The Glivec brand of imatinib mesilate (supplied by Novartis) is fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST only, see SA1460 in Section B of the Pharmaceutical Schedule~~

Cap 100 mg – **5% DV Dec-23 to 2026**	44.93	60	**Imatinib-Rex**
Cap 400 mg – **5% DV Dec-23 to 2026**	69.76	30	**Imatinib-Rex**

192 BRENTUXIMAB VEDOTIN (new listing)

Inj 50 mg vial	5,275.18	1	Adcetris

Restricted
Initiation – relapsed/refractory Hodgkin lymphoma
Reassessment required after 6 months
All of the following:
1 Either:
  1.1 Both:
    1.1.1 Patient has relapsed/refractory CD30-positive Hodgkin lymphoma after two or more lines of chemotherapy; and
    1.1.2 Patient is ineligible for autologous stem cell transplant; or
  1.2 Both:
    1.2.1 Patient has relapsed/refractory CD30-positive Hodgkin lymphoma; and
    1.2.2 Patient has previously undergone autologous stem cell transplant; and
2 Patient has not previously received funded brentuximab vedotin; and
3 Response to brentuximab vedotin treatment is to be reviewed after a maximum of 6 treatment cycles; and
4 Brentuximab vedotin to be administered at doses no greater than 1.8 mg/kg every 3 weeks.

Continuation – relapsed/refractory Hodgkin lymphoma
Reassessment required after 9 months
All of the following:
1 Patient has achieved a partial or complete response to brentuximab vedotin after 6 treatment cycles; and

continued...

Changes to Section H Part II – effective 1 December 2023 (continued)

continued...

2 Treatment remains clinically appropriate and the patient is benefitting from treatment and treatment is being tolerated; and
3 Patient is to receive a maximum of 16 total cycles of brentuximab vedotin treatment.

Initiation – anaplastic large cell lymphoma
Reassessment required after 9 months
All of the following:
1 Patient has relapsed/refractory CD30-positive systemic anaplastic large cell lymphoma; and
2 Patient has an ECOG performance status of 0-1; and
3 Patient has not previously received brentuximab vedotin; and
4 Response to brentuximab vedotin treatment is to be reviewed after a maximum of 6 treatment cycles; and
5 Brentuximab vedotin to be administered at doses no greater than 1.8 mg/kg every 3 weeks.

Continuation – anaplastic large cell lymphoma
Reassessment required after 9 months
All of the following:
1 Patient has achieved a partial or complete response to brentuximab vedotin after 6 treatment cycles; and
2 Treatment remains clinically appropriate and the patient is benefitting from treatment and treatment is being tolerated; and
3 Patient is to receive a maximum of 16 total cycles of brentuximab vedotin treatment

228 TRASTUZUMAB **(HERCEPTIN)** (amended chemical name, restriction criteria and delisting)

➔ Inj 150 mg vial	1,350.00	1	Herceptin
➔ Inj 440 mg vial	3,875.00	1	Herceptin

~~Initiation – Early breast cancer~~
~~*Limited to 12 months treatment*~~
~~All of the following:~~
~~1 The patient has early breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and~~
~~2 Maximum cumulative dose of 106 mg/kg (12 months' treatment); and~~
~~3 Any of the following:~~
~~3.1 9 weeks' concurrent treatment with adjuvant chemotherapy is planned; or~~
~~3.2 12 months' concurrent treatment with adjuvant chemotherapy is planned; or~~
~~3.3 12 months' sequential treatment following adjuvant chemotherapy is planned; or~~
~~3.4 12 months' treatment with neoadjuvant and adjuvant chemotherapy is planned; or~~
~~3.5 Other treatment regimen, in association with adjuvant chemotherapy, is planned.~~

~~Initiation – metastatic breast cancer (patients previously treated with trastuzumab)~~
~~*Limited to 12 months treatment*~~
~~Either:~~
~~1 All of the following:~~
~~1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and~~
~~1.2 Either:~~
~~1.2.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or~~
~~1.2.2 Both:~~
~~1.2.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerable side effects; and~~
~~1.2.2.2 The cancer did not progress whilst on lapatinib; and~~
~~1.3 Either:~~
~~1.3.1 Trastuzumab will not be given in combination with pertuzumab; or~~
~~1.3.2 All of the following:~~

continued...

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 December 2023 (continued)

continued...

~~1.3.2.1 Trastuzumab to be administered in combination with pertuzumab; and~~
~~1.3.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo) adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and~~
~~1.3.2.3 The patient has good performance status (ECOG grade 0-1); and~~
~~1.4 Trastuzumab not to be given in combination with lapatinib; and~~
~~1.5 Trastuzumab to be discontinued at disease progression; or~~
~~2 All of the following:~~
~~2.1 Patient has previously discontinued treatment with trastuzumab in the metastatic setting for reasons other than severe toxicity or disease progression; and~~
~~2.2 Patient has signs of disease progression; and~~
~~2.3 Disease has not progressed during previous treatment with trastuzumab.~~

~~Initiation – Metastatic breast cancer (trastuzumab-naive patients)~~
~~*Limited to 12 months treatment*~~
~~All of the following:~~
~~1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and~~
~~2 Either:~~
~~2.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or~~
~~2.2 Both:~~
~~2.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and~~
~~2.2.2 The cancer did not progress whilst on lapatinib; and~~
~~3 Either:~~
~~3.1 Trastuzumab will not be given in combination with pertuzumab; or~~
~~3.2 All of the following:~~
~~3.2.1 Trastuzumab to be administered in combination with pertuzumab; and~~
~~3.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo) adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and~~
~~3.2.3 The patient has good performance status (ECOG grade 0-1); and~~
~~4 Trastuzumab not to be given in combination with lapatinib; and~~
~~5 Trastuzumab to be discontinued at disease progression.~~

Continuation – Metastatic breast cancer
Re-assessment required after 12 months
All of the following ~~Either~~:
~~1 All of the following:~~
1 ~~1.1~~ The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
2 ~~1.2~~ The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
3 ~~1.3~~ Trastuzumab not to be given in combination with lapatinib; and
4 ~~1.4~~ Trastuzumab to be discontinued at disease progression.~~; or~~
~~2 All of the following:~~
~~2.1 Patient has previously discontinued treatment with trastuzumab for reasons other than severe toxicity or disease progression; and~~
~~2.2 Patient has signs of disease progression; and~~
~~2.3 Disease has not progressed during previous treatment with trastuzumab.~~

Note – Herceptin inj 150 mg vial and 440 mg vial to be delisted from 1 June 2024

➔ Restriction
(Brand) indicates a brand example only. It is not a contracted product.

Changes to Section H Part II – effective 1 December 2023 (continued)

228 TRASTUZUMAB (HERZUMA) (new listing and addition of PSS)

➔ Inj 150 mg vial – **5% DV Jun-24 to 31-May-2027** ..... 100.00 1 **Herzuma**

➔ Inj 440 mg vial – **5% DV Jun-24 to 31-May-2027** ..... 293.35 1 **Herzuma**

Restricted

Initiation — Early breast cancer

Re-assessment required after 12 months

All of the following:

1 The patient has early breast cancer expressing HER-2 IHC 3+ or ISH + (including FISH or other current technology); and

2 Maximum cumulative dose of 106 mg/kg (12 months' treatment).

Renewal — Early breast cancer*

Re-assessment required after 12 months

Either:

1 All of the following:
   - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
   - 1.2 The patient received prior adjuvant trastuzumab treatment for early breast cancer; and
   - 1.3 Any of the following:
     - 1.3.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
     - 1.3.2 The patient discontinued lapatinib within 3 months due to intolerable side effects and the cancer did not progress whilst on lapatinib; or
     - 1.3.3 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
   - 1.4 Either:
     - 1.4.1 Trastuzumab will not be given in combination with pertuzumab; or
     - 1.4.2 All of the following:
       - 1.4.2.1 Trastuzumab to be administered in combination with pertuzumab; and
       - 1.4.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo) adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
       - 1.4.2.3 The patient has good performance status (ECOG grade 0-1); and
   - 1.5 Trastuzumab to be discontinued at disease progression; or

2 All of the following:
   - 2.1 Patient has previously discontinued treatment with trastuzumab in the metastatic setting for reasons other than severe toxicity or disease progression; and
   - 2.2 Patient has signs of disease progression; and
   - 2.3 Disease has not progressed during previous treatment with trastuzumab.

Note: * For patients with relapsed HER-2 positive disease who have previously received adjuvant trastuzumab for early breast cancer.

Initiation — Metastatic breast cancer

Re-assessment required after 12 months

All of the following:

1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and

2 Either:
   - 2.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
   - 2.2 The patient discontinued lapatinib within 3 months due to intolerable side effects and the cancer did not progress whilst on lapatinib; and

continued...

Changes to Section H Part II – effective 1 December 2023 (continued)

continued...

3 Either:
- 3.1 Trastuzumab will not be given in combination with pertuzumab; or
- 3.2 All of the following:
  - 3.2.1 Trastuzumab to be administered in combination with pertuzumab; and
  - 3.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo) adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
  - 3.2.3 The patient has good performance status (ECOG grade 0-1); and

4 Trastuzumab to be discontinued at disease progression.

Continuation — Metastatic breast cancer
Re-assessment required after 12 months
Either:
1 All of the following:
- 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 1.2 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
- 1.3 Trastuzumab to be discontinued at disease progression; or

2 All of the following:
- 2.1 Patient has previously discontinued treatment with trastuzumab for reasons other than severe toxicity or disease progression; and
- 2.2 Patient has signs of disease progression; and
- 2.3 Disease has not progressed during previous treatment with trastuzumab.

Initiation — Gastric, gastro-oesophageal junction and oesophageal cancer
Re-assessment required after 12 months
Both:
1 The patient has locally advanced or metastatic gastric, gastro-oesophageal junction or oesophageal cancer expressing HER-2 IHC 2+ FISH+ or IHC3+ (or other current technology); and
2 Patient has an ECOG score of 0-2.

Renewal — Gastric, gastro-oesophageal junction and oesophageal cancer
Re-assessment required after 12 months
Both:
1 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
2 Trastuzumab to be discontinued at disease progression.

SENSORY ORGANS

252 PROPAMIDINE ISETHIONATE (new listing)
Eye drops 0.1%

256 BETAXOLOL (delisting)

Eye drops 0.25%	11.80	5 ml	Betoptic S
Eye drops 0.5%	7.50	5 ml	Betoptic

Note – Betoptic S eye drops 0.25%, 5 ml and Betoptic eye drops 0.5%, 5 ml to be delisted from 1 July 2025

Changes to Section H Part II – effective 1 December 2023 (continued)

VARIOUS

261 CHLORHEXIDINE (new listing)
Soln 0.1%

262 DIATRIZOATE MEGLUMINE WITH SODIUM AMIDOTRIZOATE (new listing)
Oral liquid 660 mg per ml with sodium amidotrizoate

100 mg per ml, 100 ml bottle	399.00	10	Gastrografin S29
	496.80		Gastrografin Ger

262 IOHEXOL (new listing)

Inj 350 mg per ml (iodine equivalent), 75 ml bottle	130.00	10	Omnipaque

Note – this is a new Pharmacode listing, 2668505. Iohexol (Omnipaque) inj 350 mg per ml (iodine equivalent), 75 ml bottle, Pharmacode 319007, to be delisted 1 December 2023.

262 BARIUM SULPHATE (amended presentation description)

Grans for o~~O~~ral liq 960 mg per g (96% w/w), 176 g bottle	530.00	24	Vanilla SilQ MD
Grans for o~~O~~ral liq 980 mg per g (98% w/w), 310 g bottle	490.00	24	Vanilla SilQ HD

SPECIAL FOODS

275 LOW-GI ENTERAL FEED 1 KCAL/ML (delisting)
➔ Liquid 4.3 g protein, 11.3 g carbohydrate and
4.2 g fat per 100 ml, 1,000 ml bottle — *e.g. Nutrison Advanced Diason*

Note – *e.g Nutrison Advanced Diason* to be delisted from 1 July 2024

4.9 g fat and 1.2 g fibre per 100 ml, bag	8.68	1,000 ml	Jevity HiCal RTH

285 HIGH PROTEIN ORAL FEED 2.4 KCAL/ML (delay delist date)
Only to be used for patients currently on or would be using Fortisip or Fortisip Multi Fibre
➔ Liquid 14.6 g protein, 25.3 g carbohydrate
and 9.6 g fat per 100 ml,125 ml bottle — *e.g. Fortisip Compact Protein*

Note – *e.g. Fortisip Compact Protein* liquid 14.6 g protein, 25.3 g carbohydrate and 9.6 g fat per 100 ml, 125 ml bottle to be delisted from ~~1 December 2023~~ **1 December 2024**

Changes to Section H Part II – effective 1 December 2023 (continued)

292 GLYCOMACROPEPTIDE AND AMINO ACID CONTAINS SOME PHENYLALANINE – (delayed delisting date)

➔ Powder 20 g protein, 1.7 g carbohydrate per 32 g sachet	898.56	30	PKU Build 20 Chocolate PKU Build 20 Raspberry Lemonade PKU Build 20 Smooth PKU Build 20 Vanilla
➔ Powder 20 g protein, 4.9 g carbohydrate per 33.4 g sachet	936.00	30	PKU GMPro Ultra Lemonade
➔ Powder 20 g protein, 6.0 g carbohydrate per 35 g sachet	930.00	30	PKU sphere20 Lemon
➔ Powder 20 g protein, 6.3 g carbohydrate per 35 g sachet	930.00	30	PKU sphere20 Chocolate PKU sphere20 Red Berry PKU sphere20 Vanilla
➔ Powder 20 g protein, 6.7 g carbohydrate per 35 g sachet	930.00	30	PKU sphere20 Banana

Note – PKU GMPro Ultra Lemonade to be delisted from 1 ~~December 2023~~ **March 2024**. PKU Build 20 Chocolate, PKU Build 20 Raspberry Lemonade, PKU Build 20 Smooth, PKU Build 20 Vanilla, PKU sphere20 Lemon, PKU sphere20 Chocolate, PKU sphere20 Red Berry, PKU sphere20 Vanilla, PKU sphere20 Banana to be delisted from ~~1 January 2024~~ **March 2024**.

VACCINES

289 MENINGOCOCCAL B MULTICOMPONENT VACCINE (new listing)

➔ Inj 175 mcg per 0.5 ml prefilled syringe	0.00	1	Bexsero

Note – new Pharmacode listing, 2669668

Index
Pharmaceuticals and brands

Index
Pharmaceuticals and brands

Pharmaceutical Management Agency
Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand
Phone: 64 4 460 4990 - www.pharmac.govt.nz
Email: enquiry@pharmac.govt.nz

ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa New Zealand Government